Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-32 (Cancelled).

33. (New) A solid pharmaceutical composition for oral administration; which comprises, within one and the same phase:

a) at least one solid and micronized lipophilic active principle,

b) at least one surfactant,

c) at least one cationic polymer insoluble in water at pH greater than or equal to 5, and

d) at least one organic or inorganic acid.

34. (New) The composition of claim 33, wherein said one and the same phase is an internal phase.

35. (New) The composition of claim 33, wherein the lipophilic active principle comprises blood lipid-reducing compounds, steroid hormones, antifungal compounds, retinoids, steroidal anti-inflammatories, nonsteroidal anti-inflammatories, antiretroviral compounds, protease inhibitors, antacids, proton pump inhibitors, antiemetics, liposoluble vitamins, cardiovascular system drugs, anti-platelet aggregation compounds, anticancer compounds, plant extracts or their isolated or derived active principles, immunosuppressants, central nervous

system drugs, antimigraine compounds, antibiotics or antiparasitic compounds or a combination thereof.

36. (New) The composition of claim 35, wherein the blood lipid-reducing compounds comprise 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester (fenofibrate), bezafibrate, ciprofibrate, gemfibrozil, probucol, tiadenol, simvastatin, mevastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, cerivastatin or melinamide or a combination thereof.

37. (New) The composition of claim 35, wherein the steroid hormones comprise derived estrogens, esters of estradiol, progesterone, danazol, testosterone, testosterone esters, anti-androgens, 5α-reductase inhibitors, competitive inhibitors of testosterone, quinazoline compounds, nonsteroidal agonists/antagonists of estrogen receptors or a combination thereof.

38. (New) The composition of claim 35, wherein the antifungal compounds comprise itraconazole, miconazole, ketoconazole, fluconazole, griseofulvin, amphotericin B or terbinafine or a combination thereof.

39. (New) The composition of claim 33, wherein the lipophilic active principle is fenofibrate, progesterone or itraconazole.

40. (New) The composition of claim 33, wherein the active principle represents from 10 to 90% by weight of the total weight of the pharmaceutical composition.

41. (New) The composition of claim 33, wherein the surfactant has a hydrophilic-lipophilic balance (HLB) value greater than or equal to 15.

42. (New) The composition of claim 41, the surfactant is selected from the group consisting of sodium lauryl sulfate (HLB 40), poloxamers (HLB 16-29), macrogol ethers of organic alcohols (HLB 15-18), and sucrose esters of organic acids (HLB 15-16).

43. (New) The composition of claim 42, wherein the surfactant is sodium lauryl sulfate.

44. (New) The composition of claim 33, wherein the surfactant represents from 1 to 10% by weight of the total weight of said composition.

45. (New) The composition of claim 33, wherein the surfactant is in solid form.

46. (New) The composition of claim 44, wherein the surfactant is comicronized with the active principle.

47. (New) The composition of claim 33, wherein the active principle/surfactant ratio by weight is between 100/1 and 5/1.

48. (New) The composition of claim 33, wherein the cationic polymers insoluble in water at pH greater than or equal to 5 are acrylic polymers comprising a tertiary amine group.

49. (New) The composition of claim 48, wherein the polymers are aminoalkyl methacrylate polymers, soluble at pH below 5.

50. (New) The composition of claim 48, wherein the polymers are a terpolymer of poly(dimethylaminoethyl methacrylate), of methyl methacrylate and butyl methacrylate; and a terpolymer of poly(diethylaminoethyl methacrylate), methyl methacrylate and butyl methacrylate.

51. (New) The composition of claim 33, wherein the cationic polymer(s) insoluble in water at pH greater than or equal to 5 represent(s) from 0.5 to 15% by weight relative to the total weight of the pharmaceutical composition.

52. (New) The composition of claim 33, wherein the cationic polymer insoluble in water at pH greater than or equal to 5/active principle ratio by weight is between 1/5 and 1/30.

53. (New) The composition of claim 33, wherein the organic or inorganic acid is selected from the group consisting of citric acid, succinic acid, fumaric acid, acetic acid, phosphoric acid, sulfuric acid and hydrochloric acid.

54. (New) The composition of claim 33, wherein the organic or inorganic acid represents from 1 to 10% by weight relative to the total weight of the composition.

55. (New) The composition of claim 33, wherein the organic or inorganic acid/cationic polymer insoluble in water at pH greater than or equal to 5 ratio by weight is between 6/1 and 0.25/1.

56. (New) The composition of claim 33, wherein the lipophilic active principle/inorganic or organic acid ratio is between 1/1 and 30/1.

57. (New) The composition of claim 33, which comprises, by weight relative to the total weight of the composition:

a) 40 to 80% of fenofibrate as lipophilic active principle,

b) 2 to 10% of surfactant,

c) 2 to 10% of a terpolymer of poly(dimethylaminoethyl methacrylate), of methyl methacrylate and of butyl methacrylate, and

d) from 2.5 to 5% of an inorganic or organic acid.

58. (New) The composition of claim 33, which comprises fenofibrate as lipophilic active principle, and wherein it is at least 50% dissolved in 15 minutes, more than 80% dissolved in 30 minutes, more than 85% dissolved in 45 minutes and more than 90% dissolved in 60 minutes, as measured in accordance with the method using a paddle rotating at 75 rpm according to the European Pharmacopeia, in a dissolving medium consisting of 0.1M sodium lauryl sulfate in aqueous solution brought to 37°C.

59. (New) The composition of claim 34, wherein the internal phase comprises one or more excipients comprising diluting agents, binders, disintegrating agents, adjuvants for spraying, tableting, or lubrication and flow of powders or a combination thereof.

60. (New) The composition of claim 34, which further comprises an external phase comprising one or more excipients.

61. (New) The composition of claim 33, which is homogenous.

62. (New) The composition of claim 53, wherein said acid is an organic acid, which is succinic acid.

63. (New) A method for preparing the pharmaceutical composition of claim 33, which method comprises the steps of:

a) mixing of at least one solid and micronized lipophilic active principle, of at least one surfactant, of at least one cationic polymer insoluble in water at pH greater than or equal to 5 and of at least one organic or inorganic acid,

b) granulating or atomizing of the mixture obtained above in step a), then

c) tableting or dispensing into gelatin capsules of the mixture obtained at the end of step b).

64. (New) The method of claim 63, which further comprises after step b), and before step c), adding an external phase comprising one more excipients.

65. (New) The method of claim 63, which further comprises a preliminary step of comicronizing of the active principle with the surfactant(s).

66. (New) The method of claim 63, wherein step b) is carried out by granulation and wherein the mixing of the constituents in step a) comprises the following substeps of:

a1) preparing a solution or a suspension comprising at least one organic or inorganic acid and at least one cationic polymer insoluble in water at pH greater than or equal to 5, in a granulating liquid,

a2) spraying the mixture prepared above in step a1) onto the active principle which has been micronized and premixed with the solid surfactant or comicronized with said active principle, at a temperature compatible with the physical stability of the substances used in the formulation,

a3) recovering the fluidized granules thus obtained,

a4) calibrating the fluidized granules, and

a5) drying the fluidized granules.

67. (New) The method of claim 66, wherein the polymer is a terpolymer of poly(dimethylaminoethyl methacrylate), of methyl methacrylate and of butyl methacrylate and in that the granulating liquid is a propanol/acetone mixture.

68. (New) The method of claim 63, wherein step b) is carried out by atomization and in that step a) comprises the following substeps:

a'1) preparing an acid or buffer solution comprising an inorganic or organic acid and a strong base, said solution having a pH of less than 5,

a'2) preparing a suspension by addition, to this buffer solution, of at least one solid and micronized lipophilic active principle, of at least one surfactant optionally comicronized with said active principle and of at least one cationic polymer insoluble in water at pH greater than or equal to 5, with stirring,

a'3) atomizing said suspension, and

a'4) recovering the atomized product.